Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Normethadone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 7/20 | 0.97 |
| ▸ | DRD3 known ✓ | P35462 | 4/20 | 0.97 |
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.97 |
| ▸ | DRD4 known ✓ | P21917 | 3/20 | 0.69 |
| ▸ | OPRD1 known ✓ | P41143 | 3/20 | 0.59 |
| ▸ | OPRK1 known ✓ | P41145 | 3/20 | 0.59 |
| ▸ | KCNH2 known ✓ | Q12809 | 3/20 | 0.59 |
| ▸ | GRIN2D known ✓ | O15399 | 2/20 | 0.59 |
| ▸ | GRIN1 known ✓ | Q05586 | 2/20 | 0.59 |
| ▸ | GRIN2A known ✓ | Q12879 | 2/20 | 0.59 |
| ▸ | GRIN2B known ✓ | Q13224 | 2/20 | 0.59 |
| ▸ | GRIN2C known ✓ | Q14957 | 2/20 | 0.59 |
| ▸ | CACNA1F known ✓ | O60840 | 1/20 | 0.59 |
| ▸ | CACNA1D known ✓ | Q01668 | 1/20 | 0.59 |
| ▸ | CACNA1S known ✓ | Q13698 | 1/20 | 0.59 |
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 0.59 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.44 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.44 |
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Normethadone SCHEMBL24337 | 0.98 | OPRM1 (1.00) | OPRM1DRD3DRD2DRD4OPRD1 | |
| SCHEMBL22312321 | 0.89 | OPRM1 (0.82) | OPRM1DRD3DRD2DRD4OPRD1 | |
| SCHEMBL22313254 | 0.84 | OPRM1 (0.72) | OPRM1DRD3DRD2DRD4OPRD1 | |
| Hydrochloric Acid SCHEMBL17874190 | 0.81 | OPRM1 (0.65) | OPRM1DRD3DRD2DRD4OPRD1 | |
| SCHEMBL18994329 | 0.80 | OPRM1 (0.69) | OPRM1DRD3DRD2DRD4OPRD1 | |
| SCHEMBL9780534 | 0.79 | OPRM1 (0.67) | OPRM1DRD3DRD2DRD4OPRD1 | |
| Methane SCHEMBL5604947 | 0.79 | OPRM1 (0.67) | OPRM1DRD3DRD2DRD4OPRD1 | |
| SCHEMBL17870644 | 0.79 | OPRM1 (0.67) | OPRM1DRD3DRD2DRD4OPRD1 | |
| SCHEMBL20607354 | 0.78 | OPRM1 (0.66) | OPRM1DRD3DRD2DRD4OPRD1 | |
| SCHEMBL22313167 | 0.78 | OPRM1 (0.65) | OPRM1DRD3DRD2DRD4OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115038451-A | Multimodal compositions and methods of treatment | 阿奎斯蒂弗医疗股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| EP-2468732-B1 | 1H-Quinazoline-2,4-diones | NOVARTIS AG (CH) | 2014-08-20 | — | — | EP | disclosed |
| US-20130296332-A1 | 1H-QUINAZOLINE-2,4-DIONES | NOVARTIS AG (CH) | 2013-11-07 | — | — | US | disclosed |
| US-8513268-B2 | 1H-quinazoline-2,4-diones processes for their production, pharmaceutical compositions, and treatment for epilepsy | NOVARTIS AG (CH) | 2013-08-20 | — | — | US | disclosed |
| CN-101155789-B | 1H-quinazoline-2, 4-diones and their use as AMPA-receptor ligands | NOVARTIS AG | 2012-08-29 | — | — | CN | disclosed |
| EP-1871749-B1 | Selurampanel | NOVARTIS AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| EP-2476671-A1 | 1H-Quinazoline-2,4-diones | Novartis AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| EP-2468732-A1 | 1H-Quinazoline-2,4-diones | Novartis AG (CH) | 2012-06-27 | — | — | EP | disclosed |
| EP-2463278-A1 | 1H-QUINAZ0LINE-2,4-DIONES AND THEIR USE AS AMPA-RECEPTOR LIGANDS | Novartis AG (CH) | 2012-06-13 | — | — | EP | disclosed |
| US-20110294818-A1 | 1H-QUINAZOLINE-2,4-DIONES | NOVARTIS AG | 2011-12-01 | — | — | US | disclosed |
| CN-101035768-A | Compounds and compositions as cathepsin S inhibitors | NOVARTIS AG (CH) | 2007-09-12 | — | — | CN | disclosed |
| EP-1797883-A2 | Pharmaceutical composition comprising a cathepsin S inhibitor and an opioid | Novartis AG (CH) | 2007-06-20 | — | — | EP | disclosed |
| EP-1781623-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | Novartis AG (CH) | 2007-05-09 | — | — | EP | disclosed |
| US-20070037835-A1 | Pharmaceutical composition comprising a cathepsin s inhibitor and an opioid | NOVARTIS AG (CH) | 2007-02-15 | — | — | US | disclosed |
| WO-2006108591-A1 | 1H-QUINAZ0LINE-2,4-DIONES AND THEIR USE AS AMPA-RECEPTOR LIGANDS | NOVARTIS AG (CH) | 2006-10-19 | — | — | WO | disclosed |
| CN-1780628-A | Pharmaceutical composition comprising a cathepsin S inhibitor and an opioid | NOVARTIS AG (CH) | 2006-05-31 | — | — | CN | disclosed |
| WO-2006018284-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | NOVARTIS AG (CH) | 2006-02-23 | — | — | WO | disclosed |
| EP-1620106-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A CATHEPSIN S INHIBITOR AND AN OPIOID | Novartis AG (CH) | 2006-02-01 | — | — | EP | disclosed |
| WO-2005039593-A1 | COMBINATIONS COMPRISING AMPA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NEUROPATHIC PAIN | NOVARTIS AG (CH) | 2005-05-06 | — | — | WO | disclosed |
| WO-2004096227-A1 | PHARMACEUTICAL COMPOSITON COMPRISING A CATHEPSIN S INHIBITOR AND AN OPIOID | NOVARTIS AG (CH) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294818-A1 | 1H-QUINAZOLINE-2,4-DIONES | CYP1A2, QDPR, CYP3A7 | OPRM1 487/4885DRD3 327/4885DRD2 157/4885 |
| US-20070037835-A1 | Pharmaceutical composition comprising a cathepsin s inhibitor and an opioid | CTSS, CTSB, CTSG | OPRM1 20/4885DRD3 1870/4885DRD2 2065/4885 |
| US-20130296332-A1 | 1H-QUINAZOLINE-2,4-DIONES | CYP1A2, QDPR, CYP3A7 | OPRM1 487/4885DRD3 327/4885DRD2 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.